N/A N=553 Effect of Intra-operative Glove-changing During Cesarean Section on Post-op Complications: A Randomized Controlled Trial
Wound Complications
Primary: Composite Wound Complication — 34; 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
Neuropathy
Primary: Change in Pain as Measured by the Modified Brief Pain Index at 28 Days — -0.5; -1.06 units on a scale
Phase 1 N=10 Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
Hypertension, Pulmonary
Primary: Volume of Distribution of Radiolabeled GSK2256098 Measured by PET Scan — 1.0811; 1.3027; 0.8117; 0.5571 Milliliter per cubic centimeter(mL/cm^3)
N/A N=43 Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Primary: Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time — 420; 408; 416; 413 ms
Phase 3 N=232 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
Herpes Zoster · Herpes Zoster Vaccine
Primary: Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups — 24501.57; 1056.77 EL.U/mL
Phase 3 N=4,516 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Measles · Mumps · Rubella
Primary: Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value (by Enzyme-linked Immunosorbent Assay [ELISA]) — 90.9; 94.3…
Phase 2 N=25 Drug-drug Interaction Study
Pompe Disease
Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 1 Participants
Phase 1 N=28 The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary: Mean Arterial Blood Pressure Change — 14; 10 mmHg
Phase 4 N=20 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Complete Remission — 14 Participants
N/A N=24 Randomized Evaluation of Ten Allergy Skin Prick Test Devices
Allergic Rhinitis · Asthma · Food Allergy
Primary: Wheal Response — 6.8 mm
Phase 4 N=70 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery
Neuromuscular Blockade
Primary: Number of Participants With Increased Intra-abdominal Pressure (IAP) Alarm as > 15 mmHg — 14; 6 Participants
Phase 1 N=22 Empa/Lina FDC Food Effect Study (Japan)
Healthy
Primary: Cmax for Linagliptin — 15.1; 8.43 nmol/L
Phase 3 N=153 Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Number of Participants With Adverse Events — 11; 107 participants
N/A N=100 Duragen® Secure Post Marketing Clinical Follow-up (PMCF)
Dura Mater Nick Cut or Tear · Surgery
Primary: Patient's Outcome — 73; 7; 15; 3 Participants
Phase 1 N=24 A Study of LY2835219 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms — 111; 137 nanogram/milliliter (ng/mL)